Goranka Petrović
A5024456205- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Respiratory viral infections research
- Mosquito-borne diseases and control
- Viral Infections and Vectors
- Health disparities and outcomes
- Vector-borne infectious diseases
- Human Health and Disease
- Bacterial Infections and Vaccines
- Tuberculosis Research and Epidemiology
- Dental Research and COVID-19
- Hepatitis Viruses Studies and Epidemiology
- Diagnosis and treatment of tuberculosis
- Environmental and Social Impact Assessments
- COVID-19 diagnosis using AI
- Health and Well-being Studies
- Educational Challenges and Innovations
- Regional Development and Management Studies
- Gestational Diabetes Research and Management
- Sustainable Development and Environmental Policy
- COVID-19 and healthcare impacts
- Restraint-Related Deaths
- COVID-19 and Mental Health
Hrvatski zavod za javno zdravstvo
2015-2025
University of Oxford
2015
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 vaccine effectiveness (IVE) estimates two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against than A(H3N2): EU-PC 53% (95% CI: 41 63) 30% −3 54) A(H3N2). For EU-H, these were 44% 30 55) 14% −32 43), respectively.
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 season Europe. Among 5547 SARI ≥18 years, 2963 (53%) were vaccinated influenza. Overall VE A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% -4-39) A(H3N2) and 56% 22-75) B. During season, while hospitalisation B >55%, it ≤20% for A subtypes. While vaccination should be...
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory from five countries Europe. Bivalent provided short-term additional protection compared those vaccinated > 6 months before campaign: 80% (95% CI: 50 94) for 14–89 days post-vaccination, 15% −12 35)...
Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 VE age genetic subgroups to explore cohort. Methods We measured against (sub)clades. stratified usual groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of (I-REV) hypothesis,...
We estimated the effectiveness of adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine was 46% at 14-59 days and 34% 60-119 days, no effect thereafter. The conferred protection BA.2.86 lineage first 4 months post-vaccination.
In recent years various EU/EEA countries have experienced an influx of migrants from low and middle-income countries. 2018, the "Vaccine European New Integrated Collaboration Effort (VENICE)" survey group conducted a among 30 to investigate immunisation policies practices targeting irregular migrants, refugees asylum seekers (later called "migrants" in this report). Twenty-nine participated survey. Twenty-eight reported having national children/adolescent adult however vaccinations offered...
Introduction The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim We aimed to measure VE against PCR-confirmed SARS-CoV-2 patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 July 2022 (Omicron-dominant period). Methods In both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. defined complete...
Over the last three years an unprecedented flow of migrants arrived in Europe. There is evidence that vaccine preventable diseases have caused outbreaks migrant holding centres. These can be favored by a combination factors including low immunization coverage, bad conditions face during their exhausting journey and overcrowding within facilities. In 2017, we conducted online survey Croatia, Greece, Italy, Malta, Portugal Slovenia to explore national strategies targeting irregular migrants,...
ABSTRACT We conducted a multicentre test‐negative case–control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. provide early estimates of effectiveness newly adapted XBB.1.5 COVID‐19 vaccines against PCR‐confirmed SARS‐CoV‐2 hospitalisation. Vaccine was 49% overall, ranging between 69% at 14–29 days and 40% 60–105 post vaccination. The conferred protection hospitalisation first...
European countries have included healthcare workers (HCWs) among priority groups for COVID-19 vaccination. We established a multi-country hospital network to measure the SARS-CoV-2 incidence and effectiveness of vaccines HCWs against laboratory-confirmed infection.
A total of 52 serum samples from patients with symptoms suggestive tick-borne encephalitis virus (TBEV) infection and positive IgM and/or IgG antibodies were tested for avidity. Acute/recent TBEV was confirmed by low/borderline avidity index (AI) in 94.8% positive/IgG samples, while 5.2% high AI found indicating persisting antibodies. Majority negative/IgG (78.6%) showed consistent past infection. However, 21.3% without measurable current/recent AI. represents an additional serologic marker...
Background European-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening. Aim We aimed to identify groups foreign-born individuals residing in European countries most targeted prevention Methods The Tuberculosis Network Trials group collected, by cross-sectional survey, numbers patients Union (EU) countries, Iceland, Norway, Switzerland and the United Kingdom (UK) 2020 10 highest ranked origin terms cases each country...
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥18 years hospitalised with severe acute respiratory infection in Europe. provide early estimates of effectiveness newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine was 48% overall, ranging between 68% at 14–29 days and 40% 60–105 post vaccination. The conferred protection hospitalisation first 3.5 months...
Introduction Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim We aimed to measure VE PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these during Alpha (March–June)- and Delta (June–December)-dominant periods, Methods Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control...
Background: Due to rapid spread, the Omicron variant has become dominant SARS-CoV-2 responsible for infections worldwide. We present first detection of in Croatia which resulted cross-border spreading. Methods: Whole-genome sequencing was performed using Illumina MiniSeq system. lineages were identified PANGOLIN and GISAID databases. Results: The case (BA.1.17) emerged after a workshop held Zagreb November 2021. patient reported history previous COVID-19 received two doses an mRNA vaccine....
Introduction Some specific pregnancy disorders are known to be associated with increased incidence of long-term maternal ill health (eg, gestational diabetes late onset type 2 diabetes; pre-eclampsia arterial disease). To what degree these later conditions a consequence the woman's constitution prior rather than itself triggering changes in is unknown. Additionally, there little prospective evidence for impact pre-pregnancy risk factors on outcome pregnancy. understand importance requires...